Canada adds another layer to ebola preparedness

Rona Ambrose
Rona Ambrose
The government of Canada recently signed a $4.5 million contract with Mapp Biopharmaceutical, Inc. to have it manufacture ZMapp monoclonal antibody (mAb), a potential treatment for ebola.

The contract secures Canada's access to the possible ebola treatment, which is manufactured using two monoclonal antibodies (mAbs) discovered by scientists at the Public Health Agency of Canada's National Microbiology Laboratory and the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID).

ZMapp is an experimental treatment for ebola and has yet to be authorized for commercial use. It currently can only be used for emergency compassionate use if a patient has contracted Ebola, although the U.S. Food and Drug Administration (FDA) has approved clinical trials for the treatment in the United States and West Africa.

"Canada has dedicated considerable resources to support health, humanitarian and security efforts on Ebola at home and abroad," Rona Ambrose, Canada's minister of health said. "Investing in this promising technology strengthens our capacity to respond quickly to protect the health of Canadians."

The contract is part Canada's ebola preparedness and response plan. It comes on the heels of the country's funding clinical trials for VSV-EBOV ebola vaccine, strengthened border measures to screen travelers and the assembling of ebola rapid response teams.

Organizations in this Story

Health Canada U.S. Food and Drug Administration (FDA)

Want to get notified whenever we write about any of these organizations ?
Next time we write about any of these organizations, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.